Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease

  • STATUS
    Recruiting
  • End date
    May 1, 2024
  • participants needed
    200
  • sponsor
    RECORDATI GROUP
Updated on 26 January 2021
Investigator
Karen J. Pulaski-Liebert
Primary Contact
Massachusetts General Hospital SC - SOM230B2410 (3604.3 mi away) Contact
+7 other location
pasireotide
som230
cushing's syndrome

Summary

This is a non-interventional, multinational, multi-center post-marketing study, to further document the safety and efficacy of pasireotide s.c. administered in routine clinical practice in patients with Cushing's disease. Patients with Cushing's disease and treated with pasireotide s.c. alone and in combination with other therapies will be monitored. For this study, each enrolled patient will be followed up for 3 years after enrollment. Patients who permanently discontinue pasireotide s.c. prior to completing the 3-year observation period will be followed up for 3 months after the last dose of pasireotide s.c.

Details
Condition Cushing's disease
Treatment SOM230
Clinical Study IdentifierNCT02310269
SponsorRECORDATI GROUP
Last Modified on26 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Male or female patients aged 18 years or older with a diagnosis of Cushing's disease for whom surgery has failed or for whom surgery is not an option
Patients must be treated with pasireotide s.c. started either at the first visit for this study or prior to study entry

Exclusion Criteria

Patients with ectopic ACTH-dependent Cushing's syndrome
Patients with adrenal Cushing's syndrome
Patients with Pseudo Cushing's syndrome
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note